Resources

2024 ∙ SAGE

Meeting of the Strategic Advisory Group of Experts on Immunization, September 2024: conclusions and recommendations

2024 ∙ Conseil Supérieur de la Santé (CSS)

Vaccination against RSV (adults) – revision 2024

2024 ∙ Fabienne Krauer, Felix Guenther, Marina Treskova-Schwarzbach, Viktoria Schoenfeld, Mihaly Koltai, Mark Jit, David Hodgson, Udo Schneider, Ole Wichmann, Thomas Harder, Frank G. Sandmann, Flasche, S.

Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study

2024 ∙ Haute Autorité de Santé

Vaccination strategy against RSV infections in adults aged 60 and over: role of the mRESVIA vaccine (Moderna)

2024 ∙ ACIP

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the ACIP — United States, 2024

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

2024 ∙ ACIP

GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults

2024 ∙ STIKO

Resolution on the STIKO recommendation for a standard vaccination against diseases caused by respiratory syncytial viruses (RSV) for persons ≥ 75 years of age and for the indication vaccination of persons aged 60 to 74 years with risk factors

71 results found